GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (STU:SMZ1) » Definitions » Retained Earnings

Sino Biopharmaceutical (STU:SMZ1) Retained Earnings : €3,037 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sino Biopharmaceutical's retained earnings for the quarter that ended in Dec. 2023 was €3,037 Mil.

Sino Biopharmaceutical's quarterly retained earnings declined from Dec. 2022 (€3,124 Mil) to Jun. 2023 (€3,010 Mil) but then increased from Jun. 2023 (€3,010 Mil) to Dec. 2023 (€3,037 Mil).

Sino Biopharmaceutical's annual retained earnings declined from Dec. 2021 (€3,206 Mil) to Dec. 2022 (€3,124 Mil) and declined from Dec. 2022 (€3,124 Mil) to Dec. 2023 (€3,037 Mil).


Sino Biopharmaceutical Retained Earnings Historical Data

The historical data trend for Sino Biopharmaceutical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Retained Earnings Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3,205.72 3,123.77 3,037.18

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,205.72 - 3,123.77 3,009.81 3,037.18

Sino Biopharmaceutical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Sino Biopharmaceutical  (STU:SMZ1) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sino Biopharmaceutical (STU:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (STU:SMZ1) Headlines

No Headlines